Amedisys Competitors

Amedisys (NASDAQ:AMED) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Amedisys and Laboratory Co. of America's net margins, return on equity and return on assets.

Institutional & Insider Ownership

79.8% of Amedisys shares are owned by institutional investors. Comparatively, 88.7% of Laboratory Co. of America shares are owned by institutional investors. 2.8% of Amedisys shares are owned by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Amedisys has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amedisys and Laboratory Co. of America's gross revenue, earnings per share and valuation.

Laboratory Co. of America has higher revenue and earnings than Amedisys. Laboratory Co. of America is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amedisys and Laboratory Co. of America, as reported by MarketBeat.

Amedisys currently has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Laboratory Co. of America has a consensus target price of $225.1875, indicating a potential upside of 14.62%. Given Laboratory Co. of America's stronger consensus rating and higher probable upside, analysts clearly believe Laboratory Co. of America is more favorable than Amedisys.

Summary

Laboratory Co. of America beats Amedisys on 8 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent ratings for Amedisys and Quest Diagnostics, as provided by MarketBeat.

Amedisys currently has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Quest Diagnostics has a consensus target price of $126.6471, indicating a potential upside of 1.86%. Given Amedisys' stronger consensus rating and higher possible upside, research analysts clearly believe Amedisys is more favorable than Quest Diagnostics.

Profitability

This table compares Amedisys and Quest Diagnostics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Amedisys and Quest Diagnostics' top-line revenue, earnings per share and valuation.

Quest Diagnostics has higher revenue and earnings than Amedisys. Quest Diagnostics is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.8% of Amedisys shares are owned by institutional investors. Comparatively, 78.9% of Quest Diagnostics shares are owned by institutional investors. 2.8% of Amedisys shares are owned by company insiders. Comparatively, 1.5% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Amedisys has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Summary

Amedisys beats Quest Diagnostics on 9 of the 14 factors compared between the two stocks.

DaVita (NYSE:DVA) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares DaVita and Amedisys' net margins, return on equity and return on assets.

Volatility and Risk

DaVita has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Insider and Institutional Ownership

95.3% of DaVita shares are owned by institutional investors. Comparatively, 79.8% of Amedisys shares are owned by institutional investors. 1.0% of DaVita shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares DaVita and Amedisys' gross revenue, earnings per share (EPS) and valuation.

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for DaVita and Amedisys, as reported by MarketBeat.

DaVita currently has a consensus target price of $77.50, indicating a potential downside of 29.29%. Amedisys has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Given Amedisys' stronger consensus rating and higher probable upside, analysts clearly believe Amedisys is more favorable than DaVita.

Summary

Amedisys beats DaVita on 8 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Insider and Institutional Ownership

79.8% of Amedisys shares are owned by institutional investors. Comparatively, 83.2% of Chemed shares are owned by institutional investors. 2.8% of Amedisys shares are owned by company insiders. Comparatively, 4.0% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Amedisys and Chemed's gross revenue, earnings per share and valuation.

Chemed has lower revenue, but higher earnings than Amedisys. Chemed is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amedisys has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares Amedisys and Chemed's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amedisys and Chemed, as provided by MarketBeat.com.

Amedisys presently has a consensus price target of $252.3846, indicating a potential upside of 7.32%. Chemed has a consensus price target of $535.00, indicating a potential upside of 13.36%. Given Chemed's stronger consensus rating and higher possible upside, analysts clearly believe Chemed is more favorable than Amedisys.

Summary

Chemed beats Amedisys on 9 of the 14 factors compared between the two stocks.

LHC Group (NASDAQ:LHCG) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Profitability

This table compares LHC Group and Amedisys' net margins, return on equity and return on assets.

Institutional and Insider Ownership

79.8% of Amedisys shares are owned by institutional investors. 4.8% of LHC Group shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

LHC Group has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Valuation and Earnings

This table compares LHC Group and Amedisys' revenue, earnings per share (EPS) and valuation.

Amedisys has lower revenue, but higher earnings than LHC Group. LHC Group is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for LHC Group and Amedisys, as reported by MarketBeat.com.

LHC Group presently has a consensus target price of $198.75, indicating a potential upside of 0.98%. Amedisys has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Given Amedisys' stronger consensus rating and higher possible upside, analysts plainly believe Amedisys is more favorable than LHC Group.

Summary

Amedisys beats LHC Group on 10 of the 14 factors compared between the two stocks.

AMN Healthcare Services (NYSE:AMN) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Volatility & Risk

AMN Healthcare Services has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Valuation and Earnings

This table compares AMN Healthcare Services and Amedisys' top-line revenue, earnings per share and valuation.

Amedisys has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.1% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 79.8% of Amedisys shares are owned by institutional investors. 1.4% of AMN Healthcare Services shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for AMN Healthcare Services and Amedisys, as reported by MarketBeat.

AMN Healthcare Services currently has a consensus target price of $70.8571, suggesting a potential upside of 6.65%. Amedisys has a consensus target price of $252.3846, suggesting a potential upside of 7.32%. Given Amedisys' higher probable upside, analysts clearly believe Amedisys is more favorable than AMN Healthcare Services.

Profitability

This table compares AMN Healthcare Services and Amedisys' net margins, return on equity and return on assets.

Summary

Amedisys beats AMN Healthcare Services on 11 of the 15 factors compared between the two stocks.